Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Total 13F shares
-
151,143,703
-
Share change
-
+15,530,082
-
Total reported value
-
$2,495,633,592
-
Put/Call ratio
-
44%
-
Price per share
-
$16.51
-
Number of holders
-
248
-
Value change
-
+$260,890,342
-
Number of buys
-
128
-
Number of sells
-
104
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q4 2025
As of 31 Dec 2025,
Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by
248 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
151,143,703 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., BAILLIE GIFFORD & CO, T. Rowe Price Investment Management, Inc., Temasek Holdings (Private) Ltd, STATE STREET CORP, FMR LLC, NORGES BANK, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
248
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.